In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

被引:0
|
作者
Ewell, Steven M. [1 ]
Burton, Hannah [2 ]
Mochona, Bereket [1 ]
机构
[1] Florida A&M Univ, Dept Chem, Tallahassee, FL 32307 USA
[2] Florida A&M Univ, Inst Publ Hlth, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA
基金
美国国家卫生研究院;
关键词
molecular docking; molecular dynamics simulation; virtual screening; Computer-Aided Drug Design (CADD); receptor tyrosine kinases (RTKs); TYROSINE KINASE INHIBITORS; DESIGN; PREDICTION; DISCOVERY;
D O I
10.3390/cimb46100666
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Angiogenesis plays a pivotal role in the growth, survival, and metastasis of solid tumors, with Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) being overexpressed in many human solid tumors, making it an appealing target for anti-cancer therapies. This study aimed to identify potential lead compounds with azole moiety exhibiting VEGFR-2 inhibitory effects. A ligand-based pharmacophore model was constructed using the X-ray crystallographic structure of VEGFR-2 complexed with tivozanib (PDB ID: 4ASE) to screen the ZINC15 database. Following virtual screening, six compounds demonstrated promising docking scores and drug-likeness comparable to tivozanib. These hits underwent detailed pharmacokinetic analysis to assess their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Furthermore, Density Functional Theory (DFT) analysis was employed to investigate the molecular orbital properties of the top hits from molecular docking. Molecular dynamics (MD) simulations were conducted to evaluate the conformational stability of the complexes over a 100 ns run. Results indicated that the compounds (ZINC8914312, ZINC8739578, ZINC8927502, and ZINC17138581) exhibited the most promising lead requirements for inhibiting VEGFR-2 and suppressing angiogenesis in cancer therapy. This integrated approach, combining pharmacophore modeling, molecular docking, ADMET studies, DFT analysis, and MD simulations, provides valuable insights into the identification of potential anti-cancer agents targeting VEGFR-2.
引用
收藏
页码:11220 / 11235
页数:16
相关论文
共 50 条
  • [1] In-silico screening and In-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors
    Saraswat, Deepika
    Nehra, Sarita
    Chaudhary, Kamal Kumar
    Prasad, C. V. S. Siva
    BIOINFORMATION, 2014, 10 (05) : 273 - 280
  • [2] Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity
    Alam, A
    Herault, JP
    Barron, P
    Favier, B
    Fons, P
    Delesque-Touchard, N
    Senegas, I
    Laboudie, P
    Bonnin, J
    Cassan, C
    Savi, P
    Ruggeri, B
    Carmeliet, P
    Bono, FO
    Herbert, JM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 909 - 915
  • [3] Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
    Cheng, Kang
    Liu, Chen-Fu
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (13) : 2540 - 2564
  • [4] Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening
    Chelliah, Selvam
    Mock, Charlotta D.
    Mathew, Omana P.
    Ranganna, Kasturi
    FASEB JOURNAL, 2018, 32 (01):
  • [5] Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening
    Selvam, Chelliah
    Mock, Charlotta D.
    Mathew, Omana P.
    Ranganna, Kasturi
    Thilagavathi, Ramasamy
    MOLECULAR INFORMATICS, 2020, 39 (07)
  • [6] Vascular endothelial growth factor receptor-2 ( VEGFr-2) genetic polymorphisms as predictors to antiangiogenic therapy
    Jurado, J., Sr.
    Ortega, J. A.
    Iglesias, P.
    Garcia-Puche, J. L.
    Belon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins
    Gingras, D
    Lamy, S
    Béliveau, R
    BIOCHEMICAL JOURNAL, 2000, 348 (02) : 273 - 280
  • [8] Vascular endothelial growth factor receptor-2 (VEGFR-2) gene variations in bronchioloalveolar cell carcinoma (BAC)
    Cerri, Elisa
    Kashyap, Sonal
    Chen, Pei Xian
    Das, Soma
    Cipriani, Nicole
    Kanteti, Rajani
    Husain, Aliya
    Salgia, Ravi
    Innocenti, Federico
    CANCER RESEARCH, 2010, 70
  • [9] Vascular endothelial growth factor receptor-2 (VEGFR-2) N-glycosylation modulates angiogenic signaling
    Chandler, Kevin B.
    Leon, Deborah R.
    Meyer, Rosana D.
    Rahimi, Nader
    Costello, Catherine E.
    CANCER RESEARCH, 2017, 77
  • [10] The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF
    Anderson, Sean M.
    Chen, Tom T.
    Iruela-Arispe, M. Luisa
    Segura, Tatiana
    BIOMATERIALS, 2009, 30 (27) : 4618 - 4628